AN2 Therapeutics completes 200-patient observational study in acute melioidosis

AN2 Therapeutics (ANTX) announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care: IV meropenem or ceftazidime. Completed under a contract funded entirely by the National Institutes of Health, the study was completed in just 11 months across three sites in acute melioidosis-endemic regions, demonstrating efficient enrollment and strong site engagement. The study generated an important follow-up dataset for patients treated for acute melioidosis with current standard of care antibiotics, tracking patients for over 90 days. The results revealed a striking mortality rate of nearly 40% among confirmed melioidosis cases. Principal Investigators observed that approximately 25% of screened patients died in the short period before a definitive diagnosis of infection with the causative pathogen was confirmed and were not included in the topline mortality rate. These mortality findings highlight the serious impact of melioidosis, the critical importance of early detection and the urgent need for more effective treatment options. Due to its high mortality and ease of environmental acquisition, B. pseudomallei is classified as a high priority biothreat agent. If approved for the treatment of acute melioidosis, the Company would seek a priority review voucher and could generate revenue from U.S. and other government stockpiling, as well as from use as a treatment in disease endemic countries, including the U.S.